Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Authors:
Zhou Q; Lei X; Fu S; Liu P; Long C and 4 more

Journal:
Diabetol Metab Syndr

Publication Year: 2023

DOI:
10.1186/s13098-023-01198-4

PMCID:
PMC10614386

PMID:
37904255

Journal Information

Full Title: Diabetol Metab Syndr

Abbreviation: Diabetol Metab Syndr

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology & Metabolism

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThis study does not involve human participants. There is no patient involved in this study. Competing interestsThe authors have no conflicts of interest to declare. Competing interests The authors have no conflicts of interest to declare."

Evidence found in paper:

"Funding The present research was supported by Exploring the clinical efficacy and related mechanisms of Sancai Lianmei Granule for early remission of type 2 diabetes Based on the combination of traditional Chinese medicine and high-throughput sequencing technology (2023zd020). The design of this review was done without the involvement of any funders or sponsors."

Evidence found in paper:

"The protocol for this meta-analysis has been registered on Prospero, the international prospective register of systematic reviews, under the identifier CRD42022355940 (https://www.crd.york.ac.uk/prospero/#myprospero). We adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines for conducting, reporting and updating the systematic review and meta-analysis (Additional file : Table S1) []."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025